pyrazines has been researched along with vidarabine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S | 1 |
| Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S | 1 |
| Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Cheson, BD | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Buda, G; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A | 1 |
| Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
| Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Treon, SP | 1 |
| Bendell, J; Brown, JR; Derks, IA; Eichhorst, B; Eldering, E; Fernandes, SM; Filvaroff, EH; Garrick, B; Hallek, M; Hege, K; Kater, AP; Kersten, MJ; Michot, JM; Reinhardt, HC; Rodríguez, MS; Ter Burg, J; Thijssen, R; Trowe, T; van Bochove, GG; van Kampen, RJ | 1 |
4 review(s) available for pyrazines and vidarabine
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
4 trial(s) available for pyrazines and vidarabine
| Article | Year |
|---|---|
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine | 2006 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Topics: Bridged Bicyclo Compounds, Heterocyclic; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Nuclear Proteins; Purines; Pyrazines; Quinazolinones; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Vidarabine | 2016 |
10 other study(ies) available for pyrazines and vidarabine
| Article | Year |
|---|---|
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine | 2006 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine | 2010 |
[Modern times: back to past, back to future].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine | 2012 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |